All News
Topical therapies take centre stage
Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium.
Read Article
Real World Data on Urate Lowering Therapy
Urate lowering therapy (ULT) is the backbone therapy for long-term gout treatment and maintenance, but real-world gout management is often imperfect and suboptimal.
Read Article
Key Psoriatic Arthritis topics and updates at EULAR 2022
At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA). Here are my top picks from this year's meeting.
Read Article
#Bestinclass. #Giantcellarteritis GCA lots of novel ideas. V short prednisone- 2 months with #Tocilizumab. Not RCT. Looked safe & effective but too small to know if blindness etc are increased. Don’t suggest you try this at home...yet! @RheumNow @eular_org #EULAR2022 OP0185
Janet Pope Janetbirdope ( View Tweet)
#Bestinclass Recurrent #PMR RCT of #sarilumab v placebo. Nearly doubles sustained remission but maybe attenuating effect - flare difference over time? N=118. 🤷♀️ Dunno who I would use it in yet. LB0006 @RheumNow @eular_org #EULAR2022
Janet Pope Janetbirdope ( View Tweet)
Positive study NUT when to use the Rx? PMR RCTof 1 g #rituximab once. Over 1 yr with more steroid free remission - curves separate by 21 weeks (steroids off) POS0269 @RheumNow @eular_org #EULAR2023 when to use it-COVID risk, ?prefer IL6i
Janet Pope Janetbirdope ( View Tweet)
ARIAA: saw 18m results #EULAR2022
(alluded to at #ACR21)
High-risk ACPA+ clinically suspect arthralgias
Didn't progress to arthritis:
after 6m abatacept: 92% vs 65%
12m after abatacept stopped: 65% vs 43%
(tighter at points)
How to pick those that benefit?
POS0531 @RheumNow https://t.co/dkf1jU5gx7
David Liew drdavidliew ( View Tweet)
As #EULAR2022 comes to an end, there is still the playback that I am looking forward to watch. Here are my key Psoriatic Arthritis topics and updates from EULAR 2022 https://t.co/KNGGUJuukg @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
WATCH: #EULAR2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
https://t.co/ExCXY6Xbl4
@Janetbirdope @AurelieRheumo @Yuz6Yusof https://t.co/tIB8QrdYuI
Links:
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib: TYK2 inhibitor in pts with active SLE
Phase 2, randomized, double blind, placebo-controlled study
Met primary endpoint SRI response across all doses
No death, MACE, VTE, systemic infections
@RheumNow #EULAR2022 ABST#LB0004 https://t.co/yAM8qUZgee
Robert B Chao, MD doctorRBC ( View Tweet)
Sarilumab in pts with relapsing PMR - Phase 3 trial
Sarilumab +14 week steroid taper - higher sustained Remission than w/o sarilumab (28% vs 10%)
Less flare occurrences
Sarilumab noted to have higher incidences of neutropenia, arthralgia
@RheumNow #EULAR2022 ABST#LB0006 https://t.co/SeetkBsYI3
Robert B Chao, MD doctorRBC ( View Tweet)
Witholding MTX after both doses or only after the second dose of ChAdOx1 vaccine yields higher antibody repsonse compared to continuing MTX. Witholding MTX after second dose reduced the risk for flare. Data from MIVAC 1 and 2 #EULAR2022 @RheumNow LB https://t.co/GfL4eDXchb
Dr. Antoni Chan synovialjoints ( View Tweet)
In bDMARD-naive patients with PsA, the 24 week efficacy and safety of BKZ in BE OPTIMAL LB0001 by McInnes et al. At Week 16 ACR50 44% BKZ, 10% PBO, ADA 46%. PASI 90 at Week 16, 62% BKZ, PBO 3%, ADA 41% and benefit continued to Week 24 #EULAR2022 @RheumNow https://t.co/LRZoxzM57J
Dr. Antoni Chan synovialjoints ( View Tweet)
Great visual on how #socialmedia can further research and medical education #eular2022 @rheumnow @UnaMakris
@UTSWRheum https://t.co/3OiQ6CggnA
TheDaoIndex KDAO2011 ( View Tweet)
#EULAR2022 – Day 3 Report
We are sharing our favorite presentations from Day 3.
https://t.co/Kntt7qiHA5 https://t.co/Z3t5m81TDj
Links:
Dr. John Cush RheumNow ( View Tweet)
New biomarker for atherosclerosis, cardiovascular risk and disease activity in axSpA?
Low Irisin associated with subclinical atherosclerosis, high CV risk and more severe disease activity in axSpA
@RheumNow #EULAR2022 ABST#POS0327
Robert B Chao, MD doctorRBC ( View Tweet)
Prof Hoi @alberta_hoi Anti-Sm in SLE. Present in 17%. Assoc severe disease activity, "classic" SLE manifestations, specific serologic and proteomic profile. Argues for Sm+ SLE being a specific subset (or even a "different" disease?) @RheumNow #EULAR2022 POS0774 https://t.co/a5dToAuao9
Richard Conway RichardPAConway ( View Tweet)
Sing an ARIAA! #Bestinclass Rx of arthralgia w +MRI showed delay of #rheumatoid arthritis w #Abatacept vs #placebo. NNT to prevent 1 RA [is 8 w Rx for 1 yr & then d/c-Yrs ago #MTX delayed onset of RA but benefit waned after d/c Rx. Both ?RA spectrum POS0531 @RheumNow #EULAR2022
Janet Pope Janetbirdope ( View Tweet)
Bimekizumab: IL-17A and F inhibitor for tx of PsA - BE OPTIMAL trial reached primary endpoint: ACR50 44% vs. placebo
Efficacy as early as 2 weeks
No MACE, uveitis, IBD, deaths
@RheumNow #EULAR2022 ABST#LB0001 https://t.co/sHRRwLlChi
Robert B Chao, MD doctorRBC ( View Tweet)
72% of you would treat some high-risk subclinical arthralgias with MTX
and Marta Mosca, in the #EULAR2022 highlights, broadly agrees
OP0070 Leiden data showed better function and presenteeism. And that’s a win in my book
@RheumNow https://t.co/BqTLy4HBWR https://t.co/cwzJkH0f71
David Liew drdavidliew ( View Tweet)